Incyte
Pharmaceutical Research | Oncology Product Development | Incyte.com.
Launch date
Employees
Market cap
€11.1b
Enterprise valuation
€9.7b (Public information from Sep 2024)
Share price
$66.82 INCY
Chadds Ford Township Pennsylvania (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 2.7b | 3.0b | 3.4b | 3.7b | 4.1b | 4.6b | 5.0b |
| % growth | 24 % | 12 % | 14 % | 9 % | 12 % | 10 % | 11 % |
| EBITDA | (217m) | 611m | 632m | 905m | 336m | 1.4b | 1.7b |
| % EBITDA margin | (8 %) | 20 % | 19 % | 24 % | 8 % | 30 % | 33 % |
| Profit | (296m) | 949m | 341m | 598m | 195m | 973m | 1.2b |
| % profit margin | (11 %) | 32 % | 10 % | 16 % | 5 % | 21 % | 25 % |
| EV / revenue | 6.6x | 4.6x | 4.3x | 2.8x | 2.4x | 1.9x | 1.4x |
| EV / EBITDA | -80.8x | 22.7x | 23.2x | 11.5x | 29.8x | 6.4x | 4.3x |
| R&D budget | 2.2b | 1.5b | 1.6b | 1.6b | - | - | - |
| R&D % of revenue | 83 % | 49 % | 47 % | 44 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | IPO | |
$44.3m | Post IPO Equity | ||
| Total Funding | - | ||
Related Content
Recent News about Incyte
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Incyte
Edit
ACQUISITION by Incyte Apr 2024
ACQUISITION by Incyte Oct 2022